Yongan Pharmaceutical: 2024 net profit of 61.76 million yuan, turning losses into profits compared to the same period last year, plans to distribute 1 yuan per 10 shares.

On April 9, Yongan Pharmaceutical announced that its operating income in 2024 will be 839 million yuan, a year-on-year decrease of 13.78%. The net profit attributable to shareholders of listed companies was 61.766 million yuan, compared with a net loss of 12.313 million yuan in the same period last year. Basic earnings per share was 0.2107 yuan/share. Based on the existing total share capital of 295 million shares after deducting the shares in the special securities account for repurchase (as of the disclosure date, the company has repurchased a total of 5,537,350 shares of the company) of the share capital of 289 million shares, a cash dividend of 1 yuan (tax included) will be distributed to all shareholders for every 10 shares, and 0 bonus shares (tax included) will be given, and the share capital will not be increased by provident fund.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate app
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)